Copyright: ©Author(s) 2026.
World J Gastroenterol. Jul 7, 2026; 32(25): 119116
Published online Jul 7, 2026. doi: 10.3748/wjg.119116
Published online Jul 7, 2026. doi: 10.3748/wjg.119116
Figure 1 Reconsidering the role of metabolic dysfunction-associated steatotic liver disease in pancreatic cancer progression.
MASLD: Metabolic dysfunction-associated steatotic liver disease.
- Citation: Li YL, Zhang DJ, Zhu YY, Wang CX, Liu Q. Reconsidering the role of metabolic dysfunction-associated steatotic liver disease in pancreatic cancer progression. World J Gastroenterol 2026; 32(25): 119116
- URL: https://www.wjgnet.com/1007-9327/full/v32/i25/119116.htm
- DOI: https://dx.doi.org/10.3748/wjg.119116